By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Experimental Cholesterol Drug Cuts LDL Levels in Half After 1 Year
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > Experimental Cholesterol Drug Cuts LDL Levels in Half After 1 Year
Public HealthWellness

Experimental Cholesterol Drug Cuts LDL Levels in Half After 1 Year

Susan Scutti
Susan Scutti
Share
4 Min Read
cholesterol drug
SHARE

cholesterol drugResults from Amgen’s year-long safety and efficacy study showed monthly treatment with its experimental cholesterol drug reduced low-density lipoprotein (LDL or “bad”) cholesterol by 52 percent while causing no serious side effects in the majority of patients.

cholesterol drugResults from Amgen’s year-long safety and efficacy study showed monthly treatment with its experimental cholesterol drug reduced low-density lipoprotein (LDL or “bad”) cholesterol by 52 percent while causing no serious side effects in the majority of patients. Data from the study of the new drug, evolocumab, were simultaneously presented at the American Heart Association Scientific Sessions 2013 in Dallas.

“We look forward to Phase 3 results from our PROFICIO clinical program evaluating the safety and efficacy of two distinctive dosing options of evolocumab in a range of at-risk patient populations,” Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, stated in a press release. This next phase of testing includes 13 trials, with a combined planned enrollment of more than 28,000 patients to evaluate evolocumab when administered to multiple patient populations, including in combination with statins.

“Many patients with high cholesterol struggle to adequately reduce their LDL-C, a significant contributor to cardiovascular disease,” Michael Koren, M.D., of the Jacksonville Center for Clinical Research, announced to the press. More than 71 million American adults have high LDL cholesterol, recognized as a major risk factor for cardiovascular disease (CVD). The number one cause of death worldwide, CVD claims more lives each year than cancer, chronic lower respiratory disease, and accidents combined, according to the Centers for Disease Control and Prevention.

Evolocumab is an experimental monoclonal antibody, which is a type of protein cloned from human cells in a laboratory, and made to bind to substances in the body in order to alert the immune system to attack the target. Evolocumab binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), which degrades LDL receptors on the surface of the liver. In the absence of PCSK9, the liver is better able to remove LDL cholesterol from the blood.

A total of 1,104 patients were enrolled in the safety and efficacy study. Serious side effects occurred in 7.1 percent of patients treated with evolocumab and 6.3 percent of the control group. Overall, 81.4 percent of patients treated with evolocumab had some negative symptoms compared to 73.1 percent of the control group. The five most common side effects were nasopharyngitis (cold symptoms), upper respiratory tract infections, flu, joint pain, and back pain. 

LDL cholesterol is a health risk because it can slowly build up in the inner walls of the arteries that bring blood and therefore oxygen to both the heart and brain. Combined with other substances, it forms plaque, a hard deposit that narrows and stiffens the arteries — a condition known as atherosclerosis. If a clot forms due to LDL cholesterol, it can block a narrowed artery and cause a heart attack or stroke — also known as a “brain attack.”.

Source: Koren MJ, Giugliano RP, Raal FJ, et a. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. Circulation. 2013.

(image: shutterstock)

TAGGED:Amgencholesterol drug
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

contamination
Batch Failures And The Hidden Costs Of Contamination
Health Infographics
October 21, 2025
Medication Management For Seniors
Simplifying Medication Management For Seniors
Infographics Senior Care
October 21, 2025
Guide To Pursuing a Career in Nursing as a Foreigner in the USA
Collaboration Is the Prescription for Better Patient Care
Health
October 20, 2025
Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025

You Might also Like

Cool Infographic: Obesity Around The World: New Year’s Resolution, Anyone?

January 2, 2012
Henderson Cosmetic Dentist Marielaina Perrone DDS
Medical EducationWellness

Antibiotic Guidelines For Dental Patients

January 24, 2013

The Future of Psychiatry

June 27, 2016
care plan
Health carePublic Health

Creating an effective care plan: The ultimate guide

March 4, 2021
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?